Biogen Inc. (BIIB)
| Market Cap | 29.43B |
| Revenue (ttm) | 9.66B |
| Net Income (ttm) | 1.17B |
| Shares Out | 145.36M |
| EPS (ttm) | 8.01 |
| PE Ratio | 25.28 |
| Forward PE | 12.65 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,589,471 |
| Open | 201.21 |
| Previous Close | 201.99 |
| Day's Range | 198.11 - 205.36 |
| 52-Week Range | 189.44 - 319.76 |
| Beta | -0.01 |
| Analysts | Buy |
| Price Target | 294.44 (+45.43%) |
| Earnings Date | Apr 24, 2024 |
About BIIB
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab bio... [Read more]
Financial Performance
In 2023, Biogen's revenue was $9.84 billion, a decrease of -3.32% compared to the previous year's $10.17 billion. Earnings were $1.16 billion, a decrease of -61.89%.
Financial StatementsAnalyst Forecast
According to 25 analysts, the average rating for BIIB stock is "Buy." The 12-month stock price forecast is $294.44, which is an increase of 45.43% from the latest price.
News
Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®
CAMBRIDGE, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) ad...
3-Stock Lunch: TXN, BIIB & CMG
Jerry Castellini, Castle Ark co-founder, joins ‘Power Lunch' to discuss plays for three stocks including: Texas Instruments, Biogen and Chipotle Mexican.
Biogen Stock Rises After Earnings and on Jump in Alzheimer's Drug Sales
Biogen says first-quarter global in-market sales of Leqembi were about $19 million, nearly triple the fourth quarter of 2023.
Biogen Q1 2024 results surpass expectation despite revenue decline
Biogen Inc. (NASDAQ: BIIB), a leading biotechnology company, has released its Q1 2024 financial results, showcasing resilience and strategic growth despite facing revenue challenges. In the first quar...
Biogen first-quarter profit tops estimates as Alzheimer's drug uptake improves
New product launches progressing well, Biogen says, but total sales fall short of analyst expectations
Biogen beats quarterly profit estimates, Alzheimer's drug sales jump
Biogen beat Wall Street estimates for first-quarter profit on Wednesday, helped by a series of cost-cutting measures as older drugs face fierce competition.
Biogen tops quarterly profit estimates as cost cuts take hold, Leqembi launch picks up
Alzheimer's drug Leqembi brought in in approximately $19 million in sales for the quarter, up from the $10 million the drug generated last year.
Indivi to Collaborate with Biogen to Advance Digital Health Technology and Digital Biomarkers for Parkinson's Disease
BASEL, Switzerland--(BUSINESS WIRE)--Indivi, a leading MedTech company headquartered in Basel, Switzerland, has entered into an agreement with Biogen to advance digital health technology and develop d...
EU drug regulator does not refer to Eisai-Biogen Alzheimer's drug in meeting notes
The European Union's medicines regulator did not mention Eisai and Biogen's Alzheimer's drug in its notes and recommendations on Friday.
Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK--(BUSINESS WIRE)---- $BIIB #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biogen Inc. (“Biogen Inc.” or “t...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Biogen Inc. - BIIB
NEW YORK , March 11, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB). Such investors are advised to contact ...
AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) and Biogen Inc. (Nasdaq: BIIB) have entered into a strategic collaboration to discover antibodies for a novel target th...
Three-Stock Lunch: Biogen, DocuSign & Gap
Gina Sanchez, Lido Advisors chief market strategist, joins 'Power Lunch' to discuss stock plays for three stocks, including Biogen, DocuSign and Gap.
New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy
CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced interim 6-month biomarker data from the initial 29 participants in the open-label RESPOND study.* The Phase 4 ...
Biogen Highlights New Data at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™) 2024 Annual Meeting
CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced it will present new data from its Alzheimer's disease (AD) portfolio at the upcoming International Conference ...
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Biogen Inc. (BIIB) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Biogen Inc. (“Bio...
Biogen's QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP
CAMBRIDGE, Mass., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a posi...
EU medicines regulator backs Biogen's ALS drug
Europe's medicines regulator said on Friday that it has recommended granting a marketing authorization for Biogen's drug for a type of neurological disease known as amyotrophic lateral sclerosis (ALS)...
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Biogen Inc. (BIIB) on Behalf of Investors
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Biogen Inc. (“Biogen” or the “Company”) (NASDAQ: BIIB) investors concerning the Company's possibl...
The Law Offices of Frank R. Cruz Announces Investigation of Biogen Inc. (BIIB) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Biogen Inc. (“Biogen” or the “Company”) (NASDAQ: BIIB) on behalf of investors concerning the Company's poss...
Biogen receives subpoena from DOJ on business operations in foreign countries
Biogen has received a subpoena from the U.S. Department of Justice seeking information relating to the company's business operations in several foreign countries, the drugmaker disclosed in a filing o...
Biogen's quarterly results miss expectations amid slow launch of Alzheimer's treatment
Biogen Inc. BIIB, +1.56% on Tuesday reported fourth-quarter results that fell short of Wall Street expectations as uptake of its newer drugs failed to offset declining multiple-sclerosis product sales...
Biogen fourth-quarter profit misses on Aduhelm exit costs
Biogen missed Wall Street estimates for fourth-quarter profit on Tuesday following its decision last month to return the rights for Alzheimer's disease drug Aduhelm and on soft sales of multiple scler...
Biogen revenue and profit shrink on Aduhelm costs, slumping sales of multiple sclerosis therapies
The results come amid the rollout of Biogen and Eisai's Leqembi, the first drug found to slow the progression of Alzheimer's to win FDA approval.
Biogen's rare genetic disorder drug gets approval in EU
Biogen said on Monday the European Commission has approved its drug for treating a rare genetic disorder that causes progressive damage to the nervous system, in adults and adolescents aged 16 years a...